Table 1. Population Characteristics of the VALID and EARLI cohorts for all patients that met the AECC criteria for ARDS.
Data are presented as n (%), mean (± Standard deviation), or median (interquartile range).
| VALID (n = 624) | EARLI (n = 335) | |
|---|---|---|
| Age (Years) | 53 (± 17) | 66 (± 17) |
| Sex: Female | 261 (42%) | 147 (44%) |
| Race: White | 544 (87%) | 165 (49%) |
| Weight (kg) | 84 (± 27) | 76 (± 30) |
| Alcohol abuse | 107 (17%) | 46 (14%) |
| Current smoker | 223 (36%) | 49 (15%) |
| Diabetes | 151 (24%) | 79 (29%) |
| Chronic liver disease | 51 (8%) | 24 (7%) |
| Temperature (°C) | 38 (± 1.1) | 38 (± 1.4) |
| Heart rate (beats.min −1 ) | 122 (± 21) | 126 (± 27) |
| Systolic blood pressure (mmHg) | 87 (± 16) | 86 (± 21) |
| Hypoxia Category | ||
| Mild | 155 (25%) | 84 (25%) |
| Moderate | 263 (42%) | 126 (38%) |
| Severe | 206 (33%) | 125 (37%) |
| PaCO2 (mmHg) | 49 (± 14) | 43 (± 16) |
| Tidal Volume (mL) | 441 (± 77) | 432 (± 79) |
| Respiratory rate (breaths.min −1 ) | 29 (24 – 35) | 35 (30 – 40) |
| Haematocrit (%) | 29.6 (± 7) | 30.4 (± 7) |
| White cell count (10 3 /μL) | 16.2 (± 12) | 15.0 (± 13) |
| Platelets (10 3 /μL) | 167 (± 113) | 169 (± 105) |
| Sodium (mmol/L) | 139 (± 5) | 135 (± 6) |
| Creatinine (mg/dL) | 1.8 (± 1.5) | 2.1 (± 2.2) |
| Bicarbonate (mmol/L) | 21 (± 5) | 21 (± 6) |
| Albumin (g/dL) | 2.6 (± 0.6) | 2.5 (± 0.7) |
| Bilirubin (mg/dL) | 1.1 (0.7 – 2.1) | 1.0 (0.7 – 1.5) |
| Interleukin-6 (pg/mL) | 55 (21 – 209) | 191 (51 – 2471) |
| Interleukin-8 (pg/mL) | 16 (7 – 60) | 32 (12 – 210) |
| Soluble tumor-necrosis factor receptor-1 (pg/mL) | 2384 (1467 – 4253) | 4053 (2246 – 10116) |
| Intercellular adhesion molecule 1 (ng/mL) | 413 (271 – 677) | 667 (347 – 1241) |
| Protein C (% control) | 66 (± 39) | 90 (± 68) |
| Plasminogen activator inhibitor 1 (ng/mL) | 19.6 (9 – 37) | 8 (3 – 30) |
| Primary ARDS risk factor | ||
| Vasopressor use at baseline | 268 (43%) | 212 (63%) |
| Invasive Ventilation at baseline | 500 (80%) | 225 (68%) |
| APACHE II Score | 28 (± 8) | 30 (± 10) |
| Ventilator Free Days (censored at day 28) | 18 (4 – 24) | 21 (0 – 26) |
| In-hospital Mortality * | 167 (27%) | 137 (41%) |
*
Followed up to day 60 in EARLI and to discharge in VALID